Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review
Irritable bowel syndrome (IBS) is a multifactorial condition with principal symptoms of pain and altered bowel function. The kappa-opioid agonist asimadoline is being evaluated in Phase III as a potential treatment for IBS. Asimadoline, to date, has shown a good safety profile and the target Phase I...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278196/ |